Market Intelligence, Clinical Progress, and High-Purity Reagents for Duchenne Muscular Dystrophy (DMD) Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for Dystrophin drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | Dystrophin Domain-Specific & Micro-dystrophin Proteins: ABD (N-terminal), Rod domain (spectrin repeats), Cysteine-rich (CRD), C-terminal, and Micro-dystrophin constructs (e.g., ΔR3-R21). High purity (>95%), Endotoxin <1EU/µg. Sequence Verified. | View DMD Products |
| Gene Delivery | DMD Lentivirus / Promise-ORF: Full-length ORF (codon-optimized) or Mini/Micro-dystrophin variants for stable cell line generation. HEK293 packaged. | View DMD Products |
| Benchmark Ab | Anti-Dystrophin Recombinant mAb (e.g., Clone MANDYS106): Positive control for Western, ELISA, IHC. | View DMD Products |
| Validator | DMD siRNA Set: For knockdown verification and specificity controls in gene restoration studies. | View DMD Products |
| Related Target A | Utrophin (UTRN): Compensatory structural homolog; critical for off-target screening and utrophin upregulator programs. | View UTRN Products |
| Related Target B | Myostatin (MSTN): Muscle growth inhibitor; combination therapy target to prevent atrophy. | View MSTN Products |
| Related Target C | Alpha-Sarcoglycan (SGCA): Dystrophin-associated glycoprotein complex (DGC) member; stability assay component. | View SGCA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Full-length protein instability (>400 kDa) / Standardization | Domain-truncated constructs (ABD, Rod repeats, CRD, CT) and high-purity (>95%) recombinant micro-dystrophin calibrators for WB/LC-MS. Theoretical MW calculated. |
| Antibody Cross-Reactivity with Utrophin | Homolog panel proteins (DMD vs UTRN) verified by mass spec for specificity; full-length Utrophin available as negative control. |
| Mini-dystrophin quantification (Gene therapy PK/PD) | Matched N-terminal and C-terminal antigen standards; Sequence Verified against micro-dystrophin deletions (e.g., ΔR3-R21). |
| Lack of Controls / False Positives | Clinical Benchmark Antibodies and validated siRNA included for precise IHC, Western, and in vitro specificity checks. |
| Protein-protein interaction mapping | Dystrophin-Dystroglycan binding domain (Cysteine-rich) expressed in HEK293 with native glycosylation; DAG1 protein set available. |
Global Clinical Landscape & Future Outlook
The race for Dystrophin restoration therapies is transitioning from first-generation AAV micro-dystrophin delivery to next-generation precision editing. Elevidys (SRP-9001) by Sarepta/Roche established clinical proof-of-concept, while Pfizer discontinued its AAV9 program in 2024 due to safety concerns. The next wave targets improved muscle tropism (e.g., MyoAAV capsids), reduced immunogenicity, and functional domain optimization including nNOS-recruiting R16-R17 spectrin repeats. Major players also focus on ASO exon skipping (Sarepta, NS Pharma, Wave) and CRISPR exon editing (Vertex/Exonics, Editas). Utrophin upregulation (BioMarin, Summit) offers a genotype-agnostic alternative.
Future outlook: Competition will shift from dystrophin expression levels to durability, functionality, and safety. Key trends include: (1) Domain optimization – inclusion of nNOS-binding domain for vascular perfusion; (2) Immunogenicity management – pre-existing AAV antibody screening; (3) Combination therapies – gene therapy + myostatin/utrophin modulation; (4) Redosing strategies – non-viral delivery for repeat administration. These demand high-precision assay tools for quantification, specificity, and functional binding.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| AAV Gene Therapy (Micro-dystrophin) | Sarepta/Roche, Solid Biosciences, Pfizer (discontinued) | DMD (Early Stage/Ambulatory) | Expression Validation: Domain-specific ELISA standards (N-terminal/Rod/C-terminal) & high-purity micro-dystrophin antigens. |
| ASO / Exon Skipping | Sarepta, NS Pharma, Wave Life Sciences | DMD (Exon 45, 51, 53 skip-amenable) | Splicing & Translation Assay: Benchmark antibodies for IHC/Western and mutant Dystrophin proteins as restoration comparators. |
| CRISPR Exon Editing | Exonics (Vertex), Editas Medicine | DMD (Refractory deletions) | Knock-in validation proteins; junction-specific antigen for edited dystrophin detection. |
| Small Molecule / Readthrough | PTC Therapeutics | Nonsense Mutation DMD | Restoration Quantification: Sequence verified standards for Western/ELISA. |
| Utrophin Upregulation | BioMarin, Summit Therapeutics | DMD (Genotype-agnostic) | Utrophin vs Dystrophin cross-reactivity assays; dual-analyte quantification. |
| Monoclonal Antibody (Anti-Myostatin) | Roche, Pfizer, Scholar Rock | Muscle Atrophy in DMD | Combination Screening: MSTN/DMD dual assay reagents. |
Live Dystrophin R&D Tracker
Market data changes daily. Access the latest global pipeline status directly: